Literature DB >> 18852207

Pharmacogenomics: candidate gene identification, functional validation and mechanisms.

Liewei Wang1, Richard M Weinshilboum.   

Abstract

Pharmacogenetics is the study of the role of inheritance in variation in drug response phenotypes. Those phenotypes can range from life-threatening adverse drugs reactions at one end of the spectrum to equally serious lack of therapeutic efficacy at the other. Over the past half century, pharmacogenetics has--like all of medical genetics--evolved from a discipline with a focus on monogenetic traits to become pharmacogenomics, with a genome-wide perspective. This article will briefly review recent examples of the application of genome-wide techniques to clinical pharmacogenomic studies and to pharmacogenomic model systems that vary from cell line-based model systems to yeast gene deletion libraries. Functional validation of candidate genes and the use of genome-wide techniques to gain mechanistic insights will be emphasized for the establishment of biological plausibility and as essential follow-up steps after the identification of candidate genes.

Entities:  

Mesh:

Year:  2008        PMID: 18852207      PMCID: PMC2574004          DOI: 10.1093/hmg/ddn270

Source DB:  PubMed          Journal:  Hum Mol Genet        ISSN: 0964-6906            Impact factor:   6.150


  39 in total

1.  The International HapMap Project.

Authors: 
Journal:  Nature       Date:  2003-12-18       Impact factor: 49.962

Review 2.  Inheritance and drug response.

Authors:  Richard Weinshilboum
Journal:  N Engl J Med       Date:  2003-02-06       Impact factor: 91.245

3.  Natural variation in human gene expression assessed in lymphoblastoid cells.

Authors:  Vivian G Cheung; Laura K Conlin; Teresa M Weber; Melissa Arcaro; Kuang-Yu Jen; Michael Morley; Richard S Spielman
Journal:  Nat Genet       Date:  2003-02-03       Impact factor: 38.330

4.  Enhanced proteasomal degradation of mutant human thiopurine S-methyltransferase (TPMT) in mammalian cells: mechanism for TPMT protein deficiency inherited by TPMT*2, TPMT*3A, TPMT*3B or TPMT*3C.

Authors:  H L Tai; M Y Fessing; E J Bonten; Y Yanishevsky; A d'Azzo; E Y Krynetski; W E Evans
Journal:  Pharmacogenetics       Date:  1999-10

Review 5.  Statin-associated myopathy.

Authors:  Paul D Thompson; Priscilla Clarkson; Richard H Karas
Journal:  JAMA       Date:  2003-04-02       Impact factor: 56.272

6.  Thiopurine S-methyltransferase pharmacogenetics: chaperone protein association and allozyme degradation.

Authors:  Liewei Wang; William Sullivan; David Toft; Richard Weinshilboum
Journal:  Pharmacogenetics       Date:  2003-09

7.  Thiopurine S-methyltransferase pharmacogenetics: autophagy as a mechanism for variant allozyme degradation.

Authors:  Fang Li; Liewei Wang; Rebecca J Burgess; Richard M Weinshilboum
Journal:  Pharmacogenet Genomics       Date:  2008-12       Impact factor: 2.089

8.  Epstein-Barr virus latent membrane protein 1 induces micronucleus formation, represses DNA repair and enhances sensitivity to DNA-damaging agents in human epithelial cells.

Authors:  Ming-Tsan Liu; Yi-Ren Chen; Shu-Chuan Chen; Chi-Yuan Hu; Chang-Shen Lin; Yu-Ting Chang; Won-Bo Wang; Jen-Yang Chen
Journal:  Oncogene       Date:  2004-04-01       Impact factor: 9.867

9.  Lytic induction therapy for Epstein-Barr virus-positive B-cell lymphomas.

Authors:  Wen-hai Feng; Gregory Hong; Henri-Jacques Delecluse; Shannon C Kenney
Journal:  J Virol       Date:  2004-02       Impact factor: 5.103

Review 10.  Transcriptomic analysis of the NCI-60 cancer cell lines.

Authors:  John N Weinstein; Yves Pommier
Journal:  C R Biol       Date:  2003 Oct-Nov       Impact factor: 1.583

View more
  24 in total

1.  Replication of past candidate loci for common diseases and phenotypes in 100 genome-wide association studies.

Authors:  Konstantinos C M Siontis; Nikolaos A Patsopoulos; John P A Ioannidis
Journal:  Eur J Hum Genet       Date:  2010-03-17       Impact factor: 4.246

2.  Quantitative- and phospho-proteomic analysis of the yeast response to the tyrosine kinase inhibitor imatinib to pharmacoproteomics-guided drug line extension.

Authors:  Sandra C Dos Santos; Nuno P Mira; Ana S Moreira; Isabel Sá-Correia
Journal:  OMICS       Date:  2012-07-09

Review 3.  Sequencing technologies - the next generation.

Authors:  Michael L Metzker
Journal:  Nat Rev Genet       Date:  2009-12-08       Impact factor: 53.242

Review 4.  Germline prognostic markers for urinary bladder cancer: obstacles and opportunities.

Authors:  David W Chang; Jian Gu; Xifeng Wu
Journal:  Urol Oncol       Date:  2012 Jul-Aug       Impact factor: 3.498

5.  Genetic epidemiology of pharmacogenetic variants in South East Asian Malays using whole-genome sequences.

Authors:  A Sivadas; M Z Salleh; L K Teh; V Scaria
Journal:  Pharmacogenomics J       Date:  2016-05-31       Impact factor: 3.550

Review 6.  Gene--environment-wide association studies: emerging approaches.

Authors:  Duncan Thomas
Journal:  Nat Rev Genet       Date:  2010-04       Impact factor: 53.242

7.  FKBP5 genetic variation: association with selective serotonin reuptake inhibitor treatment outcomes in major depressive disorder.

Authors:  Katarzyna A Ellsworth; Irene Moon; Bruce W Eckloff; Brooke L Fridley; Gregory D Jenkins; Anthony Batzler; Joanna M Biernacka; Ryan Abo; Abra Brisbin; Yuan Ji; Scott Hebbring; Eric D Wieben; David A Mrazek; Richard M Weinshilboum; Liewei Wang
Journal:  Pharmacogenet Genomics       Date:  2013-03       Impact factor: 2.089

8.  GWAS or Gee Whiz, PSAS or Pshaw: elucidating the biologic and clinical significance of genetic variation in cardiovascular disease.

Authors:  Andrew P Landstrom; Michael J Ackerman
Journal:  Heart Rhythm       Date:  2009-09-15       Impact factor: 6.343

Review 9.  Maternal-fetal and neonatal pharmacogenomics: a review of current literature.

Authors:  Y J Blumenfeld; M F Reynolds-May; R B Altman; Y Y El-Sayed
Journal:  J Perinatol       Date:  2009-11-19       Impact factor: 2.521

Review 10.  Cardiovascular pharmacogenomics and individualized drug therapy.

Authors:  Naveen L Pereira; Richard M Weinshilboum
Journal:  Nat Rev Cardiol       Date:  2009-08-25       Impact factor: 32.419

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.